OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $4.06.

OncoCyte Stock Performance

Shares of OCX stock opened at $2.84 on Friday. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34. The stock has a 50 day moving average of $3.05 and a 200-day moving average of $2.96.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at $99,999.90. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of OncoCyte stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 1.58% of the stock is owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.